The Effect of Subclinical Leaflet Thrombosis and Prosthesis Type on Transcatheter Aortic Valve Degeneration (POPular PET TAVI)
Key facts
- Where
- Copenhagen, DenmarkSee the site
Where in Denmark
- RigshospitaletCopenhagen, DenmarkContact: Prof. O. De Backer, MD, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- St. Antonius Hospital
- Trial code
- NCT05758662
- Record updated
- 19 May 2026
- Original description
A multicentre cross-sectional cohort study to assess the difference in bioprosthetic micro-calcification activity, detected with 18F-NaF PET-CT, as early marker of transcatheter valve degeneration, between patients with vs. without subclinical leaflet thrombosis at five years after TAVI; and between patients with intra-annular vs. supra-annular TAVI prostheses.Read full original descriptionShow less
The Effect of Subclinical Leaflet Thrombosis and Prosthesis Type on Transcatheter Aortic Valve Degeneration
A multicentre cross-sectional cohort study to assess the difference in bioprosthetic micro-calcification activity, detected with 18F-NaF PET-CT, as early marker of transcatheter valve degeneration, between patients with vs. without subclinical leaflet thrombosis at five years after TAVI; and between patients with intra-annular vs. supra-annular TAVI prostheses.
Inclusion: Successful TAVI with Sapien or CoreValve Evolut prosthesis about 5 years ago; Able to undergo hybrid 18F-NaF PET-CT imaging and transthoracic echocardiography; Written informed consent.
Exclusion: Known severe renal insufficiency; History of valve-in-valve procedure; History of aortic valve re-intervention (including percutaneous paravalvular leak closure); Temporary or chronic oral anticoagulation use after TAVI; Known severe paravalvular regurgitation.